Clinical Trials
24 trialsNCT05328440 2023-09-25
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Henan Cancer Hospital
Phase 2 Unknown
NCT05806047 2023-04-10
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
Fudan University
Phase 2 Unknown
NCT05806671 2023-04-10
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05411380 2022-11-04
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Phase 2 Unknown
NCT05577923 2022-10-13
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Phase 2 Unknown
NCT05186545 2022-09-02
An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT04999540 2021-08-11
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
Guangdong Women and Children Hospital
Phase 2 Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04034589 2020-12-22
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT03024580 2019-08-15
MEGA
Instituto Nacional de Cancer, Brazil
Phase 2 Unknown
NCT04033172 2019-07-25
Pyrotinib
ChineseAMS
Phase 2 Unknown
NCT00006903 2019-03-20
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
GOG Foundation
Phase 2 Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02000193 2018-07-10
FANCY
Sun Yat-sen University
Phase 2 Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03202862 2017-06-29
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
Fudan University
Phase 2 Unknown
NCT01266213 2017-05-01
FLAG
Samsung Medical Center
Phase 2 Unknown
NCT02646735 2017-01-02
FRIEND
ChineseAMS
Phase 2 Unknown
NCT02530411 2015-08-21
FURVA
Velindre NHS Trust
Phase 2 Unknown
NCT02072512 2014-02-26
PROOF
Hospital Affiliated to Military Medical Science, Beijing
Phase 2 Unknown
NCT00927511 2011-07-22
FIDeS
Regina Elena Cancer Institute
Phase 2 Unknown